Taiwan FDA granted the API Market License of Ponatinib HCI "GBC"
Taiwan FDA granted the in-house developed Generic Oncology (Cytotoxic) Active Pharmaceutical Ingredient Market License of Ponatinib HCI "GBC", Registration Number: MOHW-PM061473 (DMF No. : DMF(00)4373)
